Gene Therapy 2
In research facilities all around the world scientist are attempting to stop diseases at their very roots. Instead of trying to find drugs to cure illnesses they are trying to change the genes that cause the diseases. The process by which this is done is called gene therapy. Gene therapy is the deliberate alteration of the human genome for alleviation of disease. The studies of gene therapy began in the mid 1980's to early 1990's. The focus then was "treating diseases caused by such single-gene defects as hemophilia, Duchene's muscular dystrophy, and sickle-cell anemia."1 As time passed new technologies, techniques, strategies and ideas for transferring genes have been presented. William French Anderson, Michael Blaise, and Ken Culver performed the first successful gene therapy on a human in 1990. They developed a protocol for treating Adenosine deaminase (ADA) deficiency, a severe combined immune deficiency, also known as the "Boy in the Bubble disease." ADA deficiency is a result of inheriting two copies of the defective ADA gene. Possession of a normal gene leads to the continuous, regular production of ADA in cells throughout the body. Without at least one properly functioning gene, children have no way of converting
. . .
Some common words found in the essay are:
Genome Project, Patenting DNA, NGVL Gene, United Biologically, ARIAD Pharmaceuticals, Cornell University, Genesys Inc, Stock Letter, Ashanti DeSilva, Boy Bubble, gene therapy, parkinson's disease, human genome, cystic fibrosis, prostate cancer, dna sequences, gene vector, national gene, national gene vector, gene transfer, safety efficacy trials, safety efficacy, clinical safety efficacy, human genome project, efficacy trials united,
Approximate Word count = 3675
Approximate Pages = 15 (250 words per page double spaced)
|
 |
